Fate Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $3,074 | $6,772 | $1,925 | $1,676 |
Gross Profit | 3,074 | -27,832 | -2,896 | -3,209 |
EBITDA | -52,377 | -40,362 | -46,247 | -39,237 |
EBIT | -45,083 | -51,068 | -44,122 | |
Net Income | -47,678 | -38,427 | -48,004 | -44,122 |
Net Change In Cash | 3,074 | 6,772 | 1,925 | 1,676 |
Free Cash Flow | -29,914 | -32,357 | -33,436 | -36,818 |
Cash | 37,909 | 36,917 | 121,322 | 41,870 |
Basic Shares | 117,769 | 117,468 | 101,104 | 98,613 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $63,533 | $96,300 | $55,846 | $31,434 |
Gross Profit | -98,163 | 96,300 | 49,996 | -94,189 |
EBITDA | -172,229 | -294,628 | -211,144 | -124,998 |
EBIT | -190,511 | -308,386 | -216,994 | -128,085 |
Net Income | -160,928 | -255,056 | -206,301 | -170,300 |
Net Change In Cash | 63,533 | 96,300 | 55,846 | 31,434 |
Cost of Revenue | -33,764 | 82,533 | ||
Free Cash Flow | -138,416 | -283,774 | -213,574 | -44,161 |
Cash | 41,870 | 61,333 | 133,583 | 167,347 |
Basic Shares | 98,411 | 96,826 | 94,747 | 82,385 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.40 |
2024-06-30 | -$0.33 |
2024-03-31 | -$0.47 |
2023-12-31 | -$0.45 |
